FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Novan, Inc. Surges Upon Announcement of Positive Preclinical Data”
Novan, Inc. (NASDAQ: NOVN) surged over 60% in premarket trading after the company announced positive topline efficacy and safety results for the B-SIMPLE4 pivotal Phase 3 clinical study of SB206
There are currently no U.S. FDA approved therapies for the treatment of molluscum, a common, contagious skin infection, and the Company believes that its topical antiviral gel would satisfy an important patient-care need for the treatment of molluscum.
Novan, Inc. is a clinical development-stage biotechnology company focused on leveraging its proprietary nitric oxide (NO) based technology platform, NITRICIL™ to generate macromolecular New Chemical Entities (NCEs) to treat multiple indications in dermatology, men’s and women’s health, infectious diseases and gastroenterology conditions with significant unmet needs. The Company’s lead product candidate, SB206, a topical antiviral gel, for the treatment of molluscum contagiosum, is currently being evaluated in the B-SIMPLE4 pivotal Phase 3 clinical study. The Company believes that SB206 as a topical, at-home, caregiver-applied therapy with a rapid treatment benefit, if approved, would address an important patient-care need for the treatment of molluscum.
For more information, please visit: Novan, Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.